Pancreatic Ductal Adenocarcinoma Clinical Trials in Seattle, Washington

8 studies are recruiting for pancreatic ductal adenocarcinoma in Seattle, Washington right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

1. Atebimetinib + GnP as a First Line Treatment in Patients With Metastatic Pancreatic Adenocarcinoma

   The purpose of this study is to evaluate the safety and efficacy of atebimetinib in combination with modified GnP compared with SOC GnP alone.

   Stage

   Phase 3

   Ages

   18 and older

   Site

   University of Washington Fred Hutchinson Cancer Center, Seattle, Washington

   Locations

   48 in total

   Run by

   Immuneering Corporation

   See if you can join NCT07562152 on ClinicalTrials.gov

2. PTM-101 in Pancreatic Ductal Adenocarcinoma (PDAC)

   This is a multi-center, non-randomized, single-arm, open-label, phase Ib, dose escalation/dose expansion study of PTM-101 when combined with neoadjuvant chemotherapy for the treatment of treatment-naïve subjects with borderline resectable and locally advanced pancreatic ductal adenocarcinoma (PDAC).

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Virginia Mason Medical Center, Seattle, Washington

   Locations

   8 in total

   Run by

   PanTher Therapeutics

   See if you can join NCT06673017 on ClinicalTrials.gov

3. Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors

   This phase I/II trial evaluates the highest safe dose, side effects, and possible benefits of tegavivint in treating patients with solid tumors that has come back (recurrent) or does not respond to treatment (refractory). Tegavivint interferes with the binding of beta-catenin to TBL1, which may hel…

   Stage

   Phase 1

   Ages

   1 to 30

   Site

   Seattle Children's Hospital, Seattle, Washington

   Locations

   21 in total

   Run by

   Children's Oncology Group

   See if you can join NCT04851119 on ClinicalTrials.gov

4. MOONRAY-01, A Study of LY3962673 in Participants With KRAS G12D-Mutant Solid Tumors

   The main purpose of this study is to assess safety \& tolerability and antitumor activity of LY3962673 as monotherapy and in combination with other chemotherapy agents in participants with KRAS G12D-mutant advanced solid tumor types. The study is expected to last approximately 5 years.

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Fred Hutchinson Cancer Center, Seattle, Washington

   Locations

   52 in total

   Run by

   Eli Lilly and Company

   See if you can join NCT06586515 on ClinicalTrials.gov

5. Study of RAS(ON) Inhibitors in Patients With Gastrointestinal Solid Tumors

   The purpose of this platform study is to evaluate the safety, tolerability, pharmacokinetics (PK), and preliminary antitumor activity of novel RAS(ON) inhibitors combined with Standard(s) of Care (SOC) or with novel agents. The current subprotocols include the following: Subprotocol A: RMC-6236 + 5…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Fred Hutchinson Cancer Center, Seattle, Washington

   Locations

   32 in total

   Run by

   Revolution Medicines, Inc.

   See if you can join NCT06445062 on ClinicalTrials.gov

6. Phase I Study of [177Lu]Lu-NNS309 in Patients With Pancreatic, Lung, Breast and Colorectal Cancers

   The purpose of this study is to evaluate the safety, tolerability, dosimetry and preliminary efficacy of [177Lu]Lu-NNS309 and the safety, dosimetry and imaging properties of [68Ga]Ga-NNS309 in patients aged ≥ 18 years with locally advanced or metastatic pancreatic ductal adenocarcinoma (PDAC), non-…

   Stage

   Phase 1

   Ages

   18 to 100

   Site

   University Of Washington, Seattle, Washington

   Locations

   29 in total

   Run by

   Novartis Pharmaceuticals

   See if you can join NCT06562192 on ClinicalTrials.gov

7. Pancreatic Cancer Early Detection Consortium

   The purpose of the Pancreatic Cancer Early Detection (PRECEDE) Consortium is to conduct research on multiple aspects of early detection and prevention of pancreatic ductal adenocarcinoma (PDAC) by establishing a multisite cohort of individuals with family history of PDAC and/or individuals carrying…

   Stage

   Not phased

   Ages

   18 to 90

   Site

   University of Washington, Seattle, Washington

   Locations

   60 in total

   Run by

   Arbor Research Collaborative for Health

   See if you can join NCT04970056 on ClinicalTrials.gov

8. A Phase 1/2 Study of VS-7375 in Patients With KRAS G12D-Mutated Solid Tumors

   This study will assess the safety and efficacy of VS-7375 alone and in combination in patients with advanced solid tumors harboring a KRAS G12D-mutation.

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Virginia Mason Medical Center, Seattle, Washington

   Locations

   14 in total

   Run by

   Verastem, Inc.

   See if you can join NCT07020221 on ClinicalTrials.gov